Form 4: BioLargo CFO Dargan Granted 300,000 Stock Options

BioLargo, Inc. Chief Financial Officer Charles K. Dargan was granted 300,000 stock options as compensation for his role.

Summary

• Charles K. Dargan, Chief Financial Officer of BioLargo, Inc. (BLGO), was granted 300,000 options to purchase common stock.
• The options have an exercise price of $0.179 per share.
• The transaction date for the option grant was February 1, 2026.
• These options become exercisable on March 1, 2026, and expire on February 1, 2036.
• The grant serves as compensation for Dargan's role as CFO from February 1, 2026, through January 31, 2027.
• Following this transaction, Dargan beneficially owns 5,931,668 derivative securities (options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating stability in key management and a standard approach to executive compensation, which aligns the CFO's interests with the company's long-term performance.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with the long-term performance of BioLargo, Inc.
• It indicates continued commitment and retention of key management personnel.

Future Outlook

The option grant implies the continued service of Charles K. Dargan as Chief Financial Officer for at least the period from February 1, 2026, through January 31, 2027, tying his incentives to the company's future performance.

Management Comments

• This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2026, through January 31, 2027.

Industry Context

StockSavvy.ai notes that granting stock options to executives is a common practice in publicly traded companies, particularly in sectors like environmental technology or biotech where BioLargo operates, to incentivize long-term performance and align executive interests with shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that executive compensation packages frequently include equity components like stock options, which is a standard practice across various industries. For instance, similar grants are seen in companies within the water treatment or clean technology sectors, such as AquaBounty Technologies (AQB) or OriginClear (OCLN), where executive incentives are often tied to long-term growth and operational milestones.
• The exercise price of $0.179, likely at or near the market price at the time of grant, is typical for compensatory options designed to reward future stock price appreciation.

Related Party Transactions

• The grant of 300,000 stock options to Charles K. Dargan, the Chief Financial Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: The option grant aims to align the CFO's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: Retention of key executives like the CFO can contribute to organizational stability and strategic continuity.

Next Steps

• Charles K. Dargan is expected to continue serving as BioLargo's Chief Financial Officer.
• The options may be exercised by the reporting person on or after March 1, 2026, until their expiration date.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event, specifically the grant of stock options to the CFO. While it indicates continued management stability and alignment of interests, it does not present new fundamental information that would warrant a change in investment recommendation. It's a standard disclosure for ongoing operations.

Keywords

BioLargo, BLGO, stock options, CFO compensation, insider transaction, executive compensation, equity grant